Profile data is unavailable for this security.
About the company
Bonesupport Holding AB is a Sweden-based orthobiologics company. It develops and commercialize injectable bioceramic bone graft substitutes which remodel to host bone and have the capability to elute drugs directly into the bone void. The marketed synthetic bone graft substitutes are CERAMENT BVF, CERAMENT G and CERAMENT V, which are based on the CERAMENT technology platform. The products are commercially available in Europe and the United States, as well as in India, Malaysia, Oman and Singapore. The products are developed to treat patients with fractures and bone voids caused by trauma and related surgery, as well as caused by infection or diseases, such as chronic osteomyelitis, revision arthroplasty and infected diabetic foot.
- Revenue in SEK (TTM)591.08m
- Net income in SEK245.02m
- Incorporated2010
- Employees110.00
- LocationBonesupport Holding ABScheelevagen 19LUND 223 70SwedenSWE
- Phone+46 462865370
- Fax+46 462865371
- Websitehttps://www.bonesupport.com
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Nykode Therapeutics ASA | 140.79m | -383.60m | 4.18bn | 168.00 | -- | 2.24 | -- | 29.71 | -1.39 | -1.39 | 0.5158 | 5.77 | 0.0601 | -- | 10.14 | -- | -16.36 | 5.65 | -19.00 | 6.38 | -- | -- | -272.47 | 18.13 | -- | -- | 0.0324 | -- | 79.99 | 282.17 | 17.75 | -- | 187.37 | -- |
Calliditas Therapeutics AB | 1.21bn | -466.18m | 5.99bn | 181.00 | -- | 16.11 | -- | 4.96 | -8.69 | -8.69 | 22.49 | 6.24 | 0.6332 | 5.02 | 8.77 | 6,667,895.00 | -24.46 | -26.46 | -30.27 | -30.27 | 94.99 | -- | -38.63 | -76.59 | 3.08 | -4.44 | 0.7427 | -- | 50.32 | -- | -13.08 | -- | -- | -- |
Gubra A/S | 319.77m | -69.45m | 7.22bn | 219.00 | -- | 9.61 | -- | 22.57 | -2.91 | -2.91 | 13.51 | 29.44 | -- | -- | -- | 936,095.90 | -- | -- | -- | -- | 56.06 | -- | -21.72 | -- | -- | -- | 0.1296 | -- | 2.82 | -- | -1,133.04 | -- | -- | -- |
Surgical Science Sweden AB | 882.85m | 233.97m | 7.38bn | 260.00 | 31.53 | 1.70 | 25.50 | 8.36 | 4.59 | 4.59 | 17.32 | 85.16 | 0.1888 | 1.87 | 6.15 | 3,395,589.00 | 5.00 | 4.49 | 5.31 | 4.78 | 69.42 | 70.06 | 26.50 | 23.75 | 3.56 | -- | -- | 0.00 | 10.01 | 68.14 | 24.47 | -- | 38.57 | -- |
Swedencare AB (publ) | 2.34bn | 58.60m | 8.73bn | 486.00 | 148.98 | 1.21 | 23.69 | 3.73 | 0.3692 | 0.3692 | 14.73 | 45.40 | 0.2395 | 2.50 | 10.23 | 4,811,523.00 | 0.6002 | 1.38 | 0.6195 | 1.43 | 55.20 | 55.34 | 2.51 | 5.10 | 1.99 | 1.96 | 0.1871 | 45.33 | 27.48 | 88.16 | -37.96 | 20.24 | 30.90 | -- |
AddLife AB | 9.69bn | 191.00m | 11.57bn | 2.30k | 62.65 | 2.41 | 10.32 | 1.19 | 1.57 | 1.57 | 79.48 | 40.69 | 0.7507 | 3.69 | 6.94 | 4,209,040.00 | 1.49 | 5.31 | 2.25 | 8.83 | 37.16 | 36.88 | 1.98 | 5.79 | 0.4541 | 1.66 | 0.5085 | 31.73 | 6.62 | 31.30 | -60.42 | 8.00 | 44.43 | -1.89 |
BioGaia AB | 1.30bn | 365.35m | 11.62bn | 210.00 | 33.03 | 5.94 | 29.76 | 8.97 | 3.62 | 3.62 | 12.84 | 20.11 | 0.5703 | 2.14 | 10.96 | 6,173,838.00 | 16.07 | 15.47 | 17.45 | 16.93 | 73.29 | 73.30 | 28.18 | 27.70 | 8.65 | -- | 0.0043 | 104.42 | 17.44 | 11.81 | -2.25 | 11.20 | 29.27 | 28.10 |
BioArctic AB | 615.99m | 229.25m | 14.49bn | 83.00 | 76.31 | 16.60 | 58.50 | 23.52 | 2.58 | 2.58 | 6.97 | 11.85 | 0.6026 | -- | -- | -- | 22.43 | 2.24 | 24.80 | 2.56 | 91.73 | 86.52 | 37.22 | 9.76 | -- | -- | 0.0047 | 0.00 | 169.83 | -2.91 | 2,150.71 | -9.69 | -- | -- |
Bonesupport Holding AB | 591.08m | 245.02m | 16.21bn | 110.00 | 66.26 | 29.94 | 64.20 | 27.42 | 3.72 | 3.72 | 9.04 | 8.24 | 1.11 | 0.7186 | 6.60 | 5,373,428.00 | 46.20 | -9.08 | 58.31 | -11.28 | 91.51 | 90.25 | 41.45 | -11.65 | 2.46 | -- | 0.0311 | -- | 79.76 | 43.65 | 459.44 | -- | 18.39 | -- |
Bavarian Nordic A/S | 11.02bn | 2.30bn | 17.95bn | 1.38k | 7.57 | 1.11 | 5.67 | 1.63 | 19.46 | 19.46 | 92.83 | 132.47 | 0.5281 | 1.92 | 6.10 | 5,121,349.00 | 11.03 | 1.21 | 13.62 | 1.48 | 65.18 | 53.72 | 20.89 | 4.06 | 1.35 | -- | 0.0139 | 0.00 | 124.14 | 69.78 | 524.66 | -- | 35.76 | -- |
Vitrolife AB | 3.50bn | -3.84bn | 22.17bn | 1.13k | -- | 1.68 | -- | 6.34 | -28.33 | -28.33 | 25.84 | 97.73 | 0.1859 | 3.76 | 6.54 | 3,242,818.00 | -20.38 | -4.57 | -21.03 | -4.78 | 56.39 | 58.38 | -109.60 | -21.89 | 2.98 | -30.31 | 0.1353 | -- | 8.60 | 24.99 | -1,077.41 | -- | -7.95 | 3.30 |
Camurus AB | 1.72bn | 431.44m | 27.95bn | 213.00 | 64.71 | 18.07 | 62.74 | 16.28 | 7.49 | 7.49 | 30.11 | 26.84 | 1.07 | 1.17 | 7.29 | 8,060,329.00 | 26.85 | -1.13 | 33.67 | -1.41 | 92.87 | 90.05 | 25.13 | -1.63 | 4.13 | -- | 0.0162 | -- | 79.52 | 103.39 | 676.63 | -- | 16.29 | -- |
ALK-Abello A/S | 7.52bn | 758.07m | 39.69bn | 2.82k | 60.03 | 6.25 | 32.74 | 5.27 | 2.09 | 2.09 | 20.90 | 20.10 | 0.7402 | 1.32 | 6.11 | 1,708,215.00 | 7.46 | 3.50 | 9.42 | 4.37 | 62.91 | 60.66 | 10.07 | 5.07 | 1.18 | 35.05 | 0.1468 | 0.00 | 6.94 | 10.60 | 45.07 | -- | 16.32 | -- |
Holder | Shares | % Held |
---|---|---|
Swedbank Robur Fonder ABas of 29 Feb 2024 | 6.37m | 9.79% |
Capital Research & Management Co. (World Investors)as of 30 Jun 2023 | 3.50m | 5.37% |
Fj�rde AP-fondenas of 29 Aug 2023 | 2.97m | 4.56% |
Handelsbanken Fonder ABas of 31 Mar 2024 | 2.56m | 3.93% |
Tredje AP-fondenas of 29 Aug 2023 | 2.25m | 3.46% |
Norges Bank Investment Managementas of 31 Dec 2022 | 1.81m | 2.78% |
Andra AP-fondenas of 29 Aug 2023 | 1.45m | 2.22% |
Lancelot Asset Management ABas of 30 Jun 2023 | 1.33m | 2.04% |
Didner & Gerge Fonder ABas of 31 Dec 2023 | 1.07m | 1.64% |
SEB Investment Management ABas of 28 Mar 2024 | 986.63k | 1.52% |